NephroDI Therapeutics Analysis: $4M Raised
What is NephroDI Therapeutics?
Pharmaceutical company targeting nephrogenic diabetes insipidus
HQ Country
Seattle, United States
Employees
1-10
Founded
2017
HQ State/Province
Washington
Funding Category
Series A
HQ Full Address
2200 32nd Ave W, Seattle, Washington 98199, United States
Product Features & Capabilities
- Oral drug for nephrogenic diabetes insipidus
- Research on AMPK therapy
Other Considerations
Announced leadership appointments including Dr. Jeff Sands as Chief Medical Officer; Entered agreement with MSRD and Otsuka for NDI treatment development
